Evaluation of cardiomyopathy

Última revisão: 27 Sep 2025
Última atualização: 30 Jul 2025

Resumo

Diagnósticos diferenciais

comuns

  • Idiopathic dilated cardiomyopathy
  • Myocarditis
  • Alcohol: dilated cardiomyopathy
Detalhes completos

Incomuns

  • Hypertrophic cardiomyopathy (HCM)
  • Idiopathic restrictive cardiomyopathy
  • Arrhythmogenic right ventricular cardiomyopathy (ARVC)
  • Brugada syndrome and other ion channelopathies
  • Conduction system disease
  • Mitochondrial disorders
  • Takotsubo syndrome
  • Peripartum: dilated cardiomyopathy
  • Tachycardia-induced: dilated cardiomyopathy
  • Amyloidosis: hypertrophic or restrictive cardiomyopathy
  • Hemochromatosis: restrictive or dilated cardiomyopathy
  • Fabry disease: hypertrophic or restrictive cardiomyopathy
  • Other lysosomal storage disease
  • Doxorubicin: dilated cardiomyopathy
  • Heavy metals/chemicals: dilated cardiomyopathy
  • Diabetes mellitus
  • Thyroid dysfunction: dilated cardiomyopathy
  • Acromegaly: hypertrophic or dilated cardiomyopathy
  • Noonan syndrome: hypertrophic cardiomyopathy
  • Lentiginosis: hypertrophic cardiomyopathy
  • Thiamine deficiency (wet beriberi): dilated cardiomyopathy
  • Friedreich ataxia/muscular dystrophy: hypertrophic and dilated cardiomyopathy
  • Deficiency of iron, niacin, selenium, or vitamin D: dilated cardiomyopathy
  • Systemic lupus erythematosus: dilated cardiomyopathy
  • Endomyocardial fibrosis/Loeffler endocarditis (hypereosinophilic syndrome)
  • Sarcoidosis
  • Electrolyte disorders
Detalhes completos

Colaboradores

Autores

Katie Linden, BMSc, MBChB

Cardiology Specialty Registrar

Belfast Health and Social Care Trust

Belfast

Northern Ireland

Declarações

KL was reimbursed by Takeda UK Ltd., the manufacturer of Replagal for Fabry disease, for travel and accommodation for a leadership course. KL was reimbursed by Sanofi Aventis, the manufacturer of Genzyme for Fabry disease, for travel and accommodation for a conference. KL received a speaker fee from Sanofi Aventis, the manufacturer of Genzyme, for a talk on Fabry disease. There was no contractual right by Sanofi to control the content of this talk.

Alison Muir, MD

Consultant Cardiologist

Royal Victoria Hospital

Belfast Health and Social Care Trust

Belfast

UK

Declarações

AM is an author of a reference cited in this topic.

Agradecimentos

KL and AM would like to gratefully acknowledge Dr Pascal McKeown, a previous contributor to this topic. PM is an author of a reference cited in this topic.

Revisores

Lubna Choudhury, MB BCh, MD, MRCPI, FACC

Professor of Medicine

Division of Cardiology

Northwestern University

Chicago

IL

Declarações

LC declares that she has no competing interests.

John Coltart, MD, FRCP, FACC, FESC, MRCS

Consultant Cardiologist

Cardio-thoracic Unit

Guy's and St Thomas' Hospital

London

UK

Divulgaciones

JC declares that he has no competing interests.

Vaikom S. Mahadevan, MBBS, MRCP

Consultant Cardiologist

Manchester Royal Infirmary

Manchester

UK

Divulgaciones

VSM declares that he has no competing interests.

Agradecimiento de los revisores por pares

Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.

Divulgaciones

Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.

Referencias

Nuestros equipos internos de evidencia y editoriales colaboran con colaboradores expertos internacionales y revisores pares para garantizar que brindemos acceso a la información más clínicamente relevante posible.

Artículos principales

Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J. 2023 Oct 1;44(37):3503-626.Texto completo  Resumen

Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines. Circulation. 2024 Jun 4;149(23):e1239-311.Texto completo  Resumen

Nagueh SF, Phelan D, Abraham T, et al. Recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: an update from the American Society of Echocardiography, in collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2022 Jun;35(6):533-69.Texto completo  Resumen

American College of Radiology. ACR appropriateness criteria: nonischemic myocardial disease with clinical manifestations. 2020 [internet publication].Texto completo

British Society of Echocardiography. Diagnosis and assessment of dilated cardiomyopathy: a guideline protocol from the British Society of Echocardiography. Jun 2017 [internet publication].Texto completo

Artículos de referencia

Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad